Company Structure and Operations - On October 1, 2024, the Company completed the spin-off of 79 convenience retail properties, totaling approximately 2.7 million square feet of gross leasable area, into Curbline Properties Corp.[14] - The Company is currently marketing several wholly-owned assets for sale, with agreements to sell two properties expected to close in the first quarter of 2026[21]. - The Company is obligated to complete redevelopment projects at properties owned by Curbline, estimated to cost $21.3 million[28]. - The Shared Services Agreement with Curbline requires the Company to provide services for a fee of 2.0% of Curbline's Gross Revenue[25]. - The Company has a 20% interest in the DTP joint venture with Chinese institutional investors, which may affect its ability to realize value from this investment[57]. - The DTP joint venture owns ten shopping centers totaling 3.4 million square feet of GLA, with a mortgage loan of approximately $380.6 million as of December 31, 2025[58]. - The Company has limited control over properties owned through the DTP joint venture, which may lead to conflicts of interest and impact cash flows[79]. - The relationship with Curbline Properties may create conflicts of interest, particularly regarding shared management and resource allocation[94]. - Agreements with Curbline Properties were not negotiated at arm's length, potentially leading to terms that may not be favorable compared to third-party negotiations[96]. - The Company is obligated to provide services to Curbline Properties until October 1, 2027, which may adversely impact its operational results and cash flow due to the disproportionate costs incurred[99]. Financial Performance - As of December 31, 2025, the Company owned 19 shopping centers with a total of 5.0 million square feet of gross leasable area, and the aggregate occupancy rate was 85.9%[16]. - The average annualized base rent per occupied square foot increased to $22.61 as of December 31, 2025, compared to $19.64 in 2024[23]. - The Company expects rental income and net income to continue decreasing due to significant disposition activity and declining property revenues[22]. - Net income attributable to common shareholders decreased to $177.861 million in 2025 from $516.031 million in 2024[170]. - Funds from Operations (FFO) attributable to common shareholders decreased to $19.429 million in 2025 from $79.443 million in 2024[170]. - Total revenues decreased to $123.649 million in 2025 from $277.467 million in 2024, a decrease of $153.818 million[182]. - The Company expects to incur significant expenses related to winding up its business, including employee severance costs and professional fees, which will impact shareholder distributions[60]. - The Company may face a potential distribution shortfall due to timing differences between cash receipt and income recognition, which could necessitate borrowing funds to meet REIT distribution requirements[113]. - The Company may face impairment charges if the estimated future cash flows from its real estate assets fall below their carrying value[65]. - The Company recorded impairment charges of $114.1 million in 2025, compared to $66.6 million in 2024, reflecting a significant increase[188]. Market and Economic Conditions - Rising interest rates could adversely impact the Company's strategy and financial performance[46]. - The Company is subject to risks related to its dependence on rental income, which may be affected by economic conditions and tenant performance[50]. - Inflationary pressures could reduce retailer profitability and consumer spending, affecting tenant demand and the Company's ability to maintain or grow rents[78]. - The Company anticipates that the economic performance of its shopping centers will be influenced by various factors, including local economic conditions and competition from e-commerce[69]. - The Company's operating expenses are relatively inflexible and may not decrease even if property revenues decline, potentially impacting cash flows and profitability[77]. - The Company is subject to potential adverse effects from changes in U.S. federal income tax laws, which could impact its ability to qualify as a REIT[116]. Asset Management and Sales - The Company plans to market its remaining properties for sale to manage liquidity and cover anticipated wind-up costs, but real estate sales prices are subject to fluctuations and may differ from book values[54]. - The Company sold its interest in the RVIP IIIB joint venture in January 2026[133]. - In 2025, the Company sold 14 wholly-owned shopping centers for an aggregate sales price of $752.5 million, using part of the proceeds to repay approximately $241.3 million of mortgage debt[163]. - The Company has a significant cash balance as of December 31, 2025, pending resolution of the Dividend Trust Portfolio joint venture[18]. - The Company plans to use proceeds from asset sales to manage liquidity, pay operating expenses, and establish a reserve fund for projected expenses during the wind-up of its business[160]. Employee and Management - The Company's workforce decreased to 155 full-time employees as of December 31, 2025, down from 172 in 2024[35]. - The Company maintains a retention plan for employees, providing one year of base salary and a medical benefits stipend of $20,000 for eligible employees terminated without cause before October 1, 2027[37]. - The Company may face challenges in retaining key management personnel due to its disposition strategy and the winding up of operations[118]. - The Company’s executive team includes David R. Lukes as President and CEO, with extensive experience in real estate management and development[38]. Legal and Compliance - The Company is subject to various legal proceedings, but management believes these will not materially affect its liquidity or financial position[139]. - The Board of Directors has discretion over the timing of distributions from asset sales, which may not align with shareholder expectations[56]. - The Board of Directors has the authority to change the Company's strategy without shareholder approval, which could impact financial conditions and distributions[67]. - The Company must distribute at least 90% of its annual net taxable income to maintain its REIT status, and failure to do so could result in significant tax liabilities[111]. - If the Company fails to qualify as a REIT, it could face substantial tax liabilities and reduced cash available for distributions to shareholders[107]. Insurance and Risk Management - The Company maintains all-risk property insurance with limits of $250 million per occurrence, but coverage may be insufficient for potential losses[85]. - The Company's properties are at risk from natural disasters, which could lead to uninsured losses and negatively impact revenue[84]. - The Company may face environmental liabilities related to its real estate investments, which could increase operating expenses and adversely affect financial results[82]. - Climate change regulations could impose substantial compliance costs and affect the Company's financial condition[83]. - The Company’s properties may be impacted by environmental contamination and climate change, which could adversely affect operations and financial results[50]. - The Audit Committee oversees the Company's cybersecurity risks and practices, receiving updates from the information technology team[127]. - The Company has implemented various cybersecurity measures, including annual training and independent security provider contracts, to mitigate risks[125].

Financial Performance - Fourth quarter net income attributable to common shareholders was $134.4 million, or $2.55 per diluted share, compared to a net loss of $13.2 million, or $0.25 per diluted share in the prior year[10]. - Fourth quarter operating funds from operations attributable to common shareholders was $2.9 million, or $0.05 per diluted share, down from $8.3 million, or $0.16 per diluted share year-over-year[10]. - The company reported a net income of $134,430,000 in Q4 2025, compared to a net loss of $5,822,000 in Q4 2024[22]. - Basic earnings per share for Q4 2025 was $2.55, a significant recovery from a loss of $0.25 in Q4 2024[22]. - Net operating income for Q4 2025 was $9,353,000, down 54.5% from $20,608,000 in Q4 2024[22]. - Total revenues for 12M 2025 were $81,155,000, slightly down from $81,967,000 in 12M 2024, representing a 1% decrease[52]. - The company reported a net loss of $0 for the fourth quarter of 2025[49]. Asset and Liability Management - Total assets decreased to $418,737,000 in Q4 2025 from $933,602,000 in Q4 2024, a reduction of 55%[26]. - Total liabilities dropped to $83,972,000 in Q4 2025 from $416,858,000 in Q4 2024, a decrease of 80%[26]. - Cash reserves increased to $119,034,000 in Q4 2025 from $54,595,000 in Q4 2024, an increase of 118%[26]. - The company reported a net debt of ($27.18 million) as of December 31, 2025, compared to a net debt of $336.25 million a year earlier, indicating a substantial improvement in financial health[31]. Revenue and Income Trends - Rental income for Q4 2025 decreased to $17,275,000 from $32,583,000 in Q4 2024, representing a decline of 47%[22]. - The total portfolio's revenue was $35,893,000, with owned GLA at 2,013,000 square feet[40]. - The net operating income (NOI) from unconsolidated joint ventures was $14,933,000 for the fourth quarter of 2025[49]. - The average occupancy rate across properties was 87.8%[55]. Leasing Activity - The leased rate was reported at 87.8% at December 31, 2025, compared to 91.1% at December 31, 2024[10]. - The company executed two new leases and 11 renewals for 74,950 square feet during the quarter[17]. - The commenced rate was reported at 85.8% at December 31, 2025, down from 90.6% at December 31, 2024[17]. - New leases in Q4 2025 totaled 2,081 square feet with an average base rent PSF of $25.92, while renewals for the same period totaled 72,869 square feet at $16.29 PSF, reflecting a 4.5% increase[34]. - The total number of renewals in Q4 2025 was 34, covering 475,869 square feet with an average rent of $14.45 per square foot, reflecting a 6.3% increase in cash[88]. Impairment and Special Distributions - An additional impairment charge of $7.5 million was recorded on one wholly-owned asset in the fourth quarter[10]. - The company incurred impairment charges of $7,500,000 in Q4 2025, compared to $0 in Q4 2024[24]. - The company paid special cash distributions aggregating $2.00 per common share for the quarter[10]. Future Outlook and Strategy - The company plans to focus on market expansion and new product development to enhance its portfolio and improve financial performance moving forward[30]. - The company plans to continue focusing on market expansion and enhancing property value through strategic acquisitions and developments[56]. - The company’s leasing strategy focuses on maintaining a balanced portfolio with a mix of large and small lease expirations to optimize rental income[91]. Property and Portfolio Management - The company sold 14 properties during the year for an aggregate price of $752.5 million and declared aggregate dividends of $6.75 per share[7]. - The company has a total of 79 convenience properties classified as discontinued operations following the spin-off of Curbline Properties[60]. - The total gross leasable area (GLA) owned and ground leased by the Company was 4,910 thousand square feet as of December 31, 2025, a decrease from 8,815 thousand square feet in December 2024[82]. - The Company reported a total of 19 operating centers as of December 31, 2025, down from 33 centers in the same period of 2024[82].

Core Viewpoint - SITE Centers Corp. is recognized as one of the 13 dividend stocks yielding over 8% [1] Group 1: Financial Updates - Piper Sandler analyst Alexander Goldfarb has lowered the price target for SITE Centers Corp. to $8 from $10 while maintaining an Overweight rating [2] - The adjustment in estimates reflects recent company announcements and refinements in Q3 2025 models [2] Group 2: Recent Transactions - On January 16, SITE Centers announced the sale of its partnership interests in the RVIP IIIB joint venture for approximately $20.8 million [3] - Earlier in December, the company agreed to sell Perimeter Pointe in Atlanta for about $48.0 million, with no proceeds used to repay mortgage debt as it was already paid off [4] Group 3: Company Overview - SITE Centers Corp. operates as a self-administered, self-managed REIT, focusing on open-air shopping centers with a fully integrated real estate platform [5]

Group 1 - Site Centers (SITC) announced the sale of Perimeter Pointe for approximately $48 million, prior to closing costs, prorations, and other closing adjustments [1] - The company did not use any proceeds from the sale to repay mortgage debt, as it had already repaid its existing mortgage facility in full on December 18 [1]

Core Viewpoint - SITE Centers Corp. has successfully sold $3.7 billion of assets since the announcement of the spin-off of Curbline Properties, with proceeds primarily used for debt repayment and shareholder distributions [2][3]. Disposition Activity - The company has sold 64 retail properties and one land parcel, declaring over $380 million in distributions to shareholders, equating to $7.39 per share since the spin-off announcement [1][2]. - As of December 4, 2025, SITE Centers owns 11 wholly-owned properties and has interests in 11 joint venture properties, with ongoing negotiations for the sale of four wholly-owned properties and one joint venture property [3]. Future Plans - SITE Centers plans to market all remaining wholly-owned retail properties, subject to market conditions, and expects to declare further distributions from sale proceeds after addressing outstanding debts and expenses [3][4]. - The company intends to maintain its common shares on the New York Stock Exchange, but may voluntarily delist to reduce operating expenses and maximize shareholder distributions [4]. Performance of Curbline Properties - Shares of Curbline Properties, distributed to SITE shareholders, have outperformed the FTSE NAREIT Shopping Center Index by over 1,550 basis points, indicating strong market demand and value creation [2].

Core Points - SITE Centers Corp. completed the sale of four properties for a total of approximately $263.6 million, with proceeds used to repay mortgage indebtedness [1][2] - The properties sold include East Hanover Plaza, Southmont Plaza, Stow Community Center, and Nassau Park Pavilion [1][2] - The company is a self-administered and self-managed REIT, publicly traded on the NYSE under the ticker symbol SITC [3] Summary by Category Property Sales - East Hanover Plaza, Southmont Plaza, and Stow Community Center were sold for approximately $126.0 million, with $38.2 million of proceeds used to repay mortgage debt [1] - Nassau Park Pavilion was sold for approximately $137.6 million, with $98.4 million of proceeds applied to fully repay a mortgage loan and an additional $7.0 million paid as a make-whole premium [2] Company Overview - SITE Centers is an owner and manager of open-air shopping centers, operating as a fully integrated real estate company [3] - The company provides additional information on its operations and investor news through its website [3]

Core Points - SITE Centers Corp. announced the sale of Paradise Village Gateway in Phoenix, AZ for $28.5 million, excluding closing costs and adjustments [1] - A portion of the net proceeds from the sale was utilized to repay $24.3 million of mortgage debt [1] Company Overview - SITE Centers Corp. is an owner and manager of open-air shopping centers, operating as a self-administered and self-managed REIT [2] - The company is publicly traded on the New York Stock Exchange under the ticker symbol SITC [2]

Core Insights - Akeso, Inc. has presented preclinical research data for its novel monoclonal antibody AK135, targeting IL-1RAP, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Group 1: Product Development - AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36, providing significant pain relief in neuropathy with good tolerability and safety profiles [2][6] - The antibody is currently in Phase I clinical trials for treating chemotherapy-induced peripheral neuropathy (CIPN) [6][11] - Preclinical studies indicate that AK135 shows dose-dependent efficacy in alleviating neuropathic pain and maintains stable body weight in treated models without significant toxicity [8] Group 2: Market Context - CIPN affects 50-90% of chemotherapy-treated patients, with 30-40% progressing to chronic neuropathic pain, highlighting the clinical significance of effective treatment options [5] - Akeso's development of AK135 addresses a critical gap in treatment options for CIPN, as current effective therapies are limited [5][6] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a robust pipeline of over 50 innovative assets across various disease areas, including cancer and autoimmune diseases [11] - The company has developed a comprehensive end-to-end drug development platform and has 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies [11]

Core Insights - Xilio Therapeutics, Inc. presented new data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, showcasing the potential of its masked T cell engager programs and tumor-activated therapies, including efarindodekin alfa and vilastobart [1][2] Group 1: Masked T Cell Engager Programs - Xilio is advancing multiple preclinical programs for masked T cell engagers targeting tumor-associated antigens such as PSMA, CLDN18.2, and STEAP1, with a collaboration with AbbVie [3] - The company's masked T cell engager programs utilize advanced formats like ATACR and SEECR, designed to enhance T cell activation and durability [4] - Preclinical data indicate that Xilio's masking technology can significantly expand the therapeutic window for T cell engagers, demonstrating potent anti-tumor activity and reduced systemic toxicity in murine models [5] Group 2: Efarindodekin Alfa - Efarindodekin alfa is an investigational tumor-activated IL-12 being evaluated in a Phase 1/2 clinical trial for patients with advanced solid tumors, with promising Phase 1 data showing a generally well-tolerated safety profile and encouraging anti-tumor activity [7][11] - As of September 2, 2025, 62 patients had been treated, with a median age of 66 years, and most patients had received multiple prior lines of therapy [7] - The treatment demonstrated partial responses in patients with advanced solid tumors, including a 33% decrease in target lesions for HPV-negative head and neck squamous cell carcinoma and a 55% decrease for uveal melanoma [11] Group 3: Vilastobart - Vilastobart is an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody being evaluated in combination with atezolizumab for advanced solid tumors and MSS mCRC [9][19] - New data presented at SITC suggest that circulating tumor DNA (ctDNA) may serve as an early biomarker for response to vilastobart treatment, with significant reductions in ctDNA correlating with treatment response [10][18] - The combination therapy is currently in Phase 1C and Phase 2 trials, with ongoing evaluations of safety and efficacy [19] Group 4: Development Plans - Xilio plans to nominate development candidates for its CLDN18.2 and STEAP1 programs in late 2025 and early 2026, respectively, with expectations to advance at least two programs into IND enabling studies by 2027 [6] - The company has completed enrollment in the Phase 1A and Phase 1B portions of the clinical trial for efarindodekin alfa, with ongoing evaluations [8][13]

Core Insights - Elicio Therapeutics announced new immunogenicity data from the Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing strong T cell responses in patients with mKRAS pancreatic ductal adenocarcinoma [1][3][6] - The company also presented preclinical data for ELI-004, indicating over 90% tumor eradication in advanced solid tumors [1][8] Group 1: ELI-002 7P Immunogenicity Data - In the AMPLIFY-7P trial, 99% of 90 evaluable patients achieved robust mKRAS-specific T cell responses, with a mean increase of 145-fold over baseline [4][6] - 85% of patients exhibited combined CD4 and CD8 T cell activation, correlating with clinical activity [4][6] - 88% of patients generated responses to their own tumor-specific mutations, indicating personalized immune activation [4][6] Group 2: ELI-004 Preclinical Data - ELI-004 demonstrated complete tumor eradication in over 90% of cases in preclinical studies, with long-term protection against recurrence [3][8] - The efficacy of ELI-004 was linked to the presence of CD8 T cells and effective lymphocyte trafficking from lymph nodes [8] - This approach suggests a promising off-the-shelf strategy for solid tumor immunotherapy [8] Group 3: Presentation Details - The findings will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting [2] - The late-breaking abstract for ELI-002 7P highlights its potential to induce robust T cell immunity across diverse HLA backgrounds [6][7] Group 4: Company Overview - Elicio Therapeutics focuses on developing novel immunotherapies targeting high-prevalence cancers, particularly those driven by KRAS mutations [14] - The company's AMP platform aims to enhance immune responses by delivering therapeutics directly to lymph nodes [12][13] - Elicio plans to expand its pipeline to include additional indications for ELI-002 and other candidates targeting different mutations [14]